Premium
Expression and Regulation of Soluble Epoxide Hydrolase in Adipose Tissue
Author(s) -
Taeye Bart M.,
Morisseau Christophe,
Coyle Julie,
Covington Joseph W.,
Luria Ayala,
Yang Jun,
Murphy Sheila B.,
Friedman David B.,
Hammock Bruce B.,
Vaughan Douglas E.
Publication year - 2010
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1038/oby.2009.227
Subject(s) - epoxide hydrolase 2 , adipose tissue , endocrinology , medicine , obesity , insulin resistance , inflammation , metabolic syndrome , chemistry , biology , enzyme , biochemistry
Obesity is an increasingly important public health issue reaching epidemic proportions. Visceral obesity has been defined as an important element of the metabolic syndrome and expansion of the visceral fat mass has been shown to contribute to the development of insulin resistance and cardiovascular disease. To identify novel contributors to cardiovascular and metabolic abnormalities in obesity, we analyzed the adipose proteome and identified soluble epoxide hydrolase (sEH) in the epididymal fat pad from C57BL/6J mice that received either a regular diet or a “western diet.” sEH was synthesized in adipocytes and expression levels increased upon differentiation of 3T3‐L1 preadipocytes. Although normalized sEH mRNA and protein levels did not differ in the fat pads from mice receiving a regular or a “western diet,” total adipose sEH activity was higher in the obese mice, even after normalization for body weight. Furthermore, peroxisome proliferator–activated receptor γ (PPARγ) agonists increased the expression of sEH in mature 3T3‐L1 adipocytes in vitro and in adipose tissue in vivo . Considering the established role for sEH in inflammation, cardiovascular diseases, and lipid metabolism, and the suggested involvement of sEH in the development of type 2 diabetes, our study has identified adipose sEH as a potential novel therapeutic target that might affect the development of metabolic and cardiovascular abnormalities in obesity.